Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Post-discharge management and outcomes of acute symptomatic seizures (ASyS) remain underexplored. We analyzed post-discharge ASM management and outcomes in ASyS patients undergoing continuous EEG (cEEG), including the role of outpatient care through a post-acute symptomatic seizure (PASS) clinic.

Methods: We performed a single-center, retrospective study of adults without epilepsy discharged on ASMs due to witnessed or suspected ASyS in 2019. A cause-specific cumulative distribution function was used to estimate outcome probabilities, and cause-specific Cox proportional hazards models examined factors influencing the first ASM discontinuation, subsequent unprovoked seizure, and death.

Results: The study evaluated 307 patients [mean 61.6 years; 51.8% females], 60.2% with confirmed ASyS [144 (46.9%) clinical ASyS; 41 (13.4%) with electrographic ASyS only]. During median 14-month follow-up, 31.9% discontinued ASM, 18.6% experienced unprovoked seizure, and 38.4% died. Based on cumulative incidence function, ASM discontinuation, unprovoked seizure, and death at 12 months occurred in 26.2%, 14.1%, and 29.3% of patients, respectively. 59.6% of alive patients without unprovoked seizures were taking ASMs. Clinical ASyS (HR 0.48; 95% CI 0.31, 0.76), electrographic ASyS only (HR 0.37; 0.17, 0.82), and acute epileptiform abnormalities (HR 0.48; 0.27, 0.84) were associated with lower ASM discontinuation. Unprovoked seizures were associated with epileptiform outpatient EEG (HR 5.40; 2.62, 11.12). PASS clinic patients discontinued ASMs 74% faster (HR 1.74; 1.12, 2.71), with 88% lower risk of unprovoked seizures (HR 0.12; 0.04, 0.34).

Interpretation: Outpatient ASM overuse in ASyS patients is common. Outpatient epileptiform abnormalities may predict unprovoked seizures. Structured outpatient care, such as PASS clinics, facilitates faster yet safer ASM discontinuation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172096PMC
http://dx.doi.org/10.1002/acn3.70039DOI Listing

Publication Analysis

Top Keywords

asm discontinuation
16
unprovoked seizures
16
management outcomes
12
outpatient care
12
unprovoked seizure
12
asys
9
acute symptomatic
8
symptomatic seizure
8
structured outpatient
8
asys patients
8

Similar Publications

Objective: Despite pharmacological advances in epilepsy treatment, one-third of patients remain pharmacoresistant and may require surgery. Despite extensive literature on epilepsy surgery, studies with follow-ups longer than 5 years are rare. Our goal was to analyze the outcomes of patients undergoing epilepsy surgery at our center, with a minimum follow-up of 15 years.

View Article and Find Full Text PDF

Epilepsy affects around 1% of the global population and often requires long-term treatment with antiseizure medications (ASMs). However, the current treatment strategy is based on clinical acumen and trial and error, resulting in only about 50% of patients remaining seizure-free for at least 12 months with first-line ASMs. Valproic acid (VPA) is a commonly prescribed first-line ASM, yet <50% of patients experience inadequate seizure control (ISC) or unacceptable adverse reactions (UARs), necessitating discontinuation.

View Article and Find Full Text PDF

Objective: To evaluate the effectiveness and safety of brivaracetam (BRV) as an add-on therapy in patients with focal onset seizures who did not achieve seizure freedom with antiseizure medication (ASM) monotherapy in routine clinical practice.

Methods: This was a retrospective, observational, multicenter study conducted across 17 neurology centers in Spain. We evaluated adult patients with focal onset epilepsy who had inadequate seizure control after at least 3 months of ASM monotherapy and were treated with dual therapy, combining BRV with their previous ASM, with the intention of maintaining this treatment for at least 6 months.

View Article and Find Full Text PDF

Efficacy, safety and tolerability of adjunctive cenobamate in pediatric and adult patients with Lennox Gastaut Syndrome.

Epilepsy Behav

August 2025

MidAtlantic Epilepsy and Sleep, LLC, 6410 Rockledge Drive, #610, Bethesda, MD 20817, USA.

Lennox-Gastaut Syndrome (LGS) is a severe developmental epileptic encephalopathy of childhood consisting of a triad of drug refractory epilepsy with multiple seizure types, cognitive impairment, and a characteristic electroencephalogram (EEG). Cenobamate (CNB) is a novel antiseizure medication (ASM) effective against focal epilepsy. Proposed mechanisms of action include inactivation of persistent sodium currents and weak positive allosteric modulation of synaptic (phasic) and extrasynaptic (tonic) GABAA receptors.

View Article and Find Full Text PDF

Challenges in the management of epilepsy associated with posterior gliosis secondary to perinatal brain injury.

Epilepsy Behav

August 2025

Department of Pediatrics, PD Hinduja National Hospital & Medical Research Center, Veer Savarkar Marg, Mahim, Mumbai 400020, India. Electronic address:

Posterior gliosis is a major substrate underlying drug resistant epilepsy (DRE) in children and young adults in low-middle income countries. Neonatal hypoglycemia and prolonged partial asphyxia either isolated or combined are major risk factors for posterior gliosis. The epilepsy associated with posterior gliosis has a spectrum of severity with early onset drug resistant epileptic encephalopathies with disabling co-morbidities at one end and pharmaco-responsive focal epilepsy in a normal child at the other.

View Article and Find Full Text PDF